21 results about "Zonulin" patented technology

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The invention belongs to the technical field of application of biomarker detection kits, and particularly relates to application of a kit for detecting fibronectin in evaluating the intestinal injury state, and the kit comprises an antibody specifically binding to fibronectin; the kit is used for detecting the fibronectin content in an excrement sample, and the intestinal injury state is evaluated based on the fibronectin content. In conclusion, the invention provides the application of the kit for detecting fibronectin, which is based on the excrement sample, is accurate in early stage and is superior to the existing marker, in evaluating the intestinal injury state.

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

A method for preparing a bionic injectable polypeptide hydrogel is provided. The hydrogel is formed using a brain extracellular matrix laminin-derived peptide DDIKVAV modified with 9-fluorenylmethoxycarbonyl (Fmoc) (Fmoc-DDIKVAV) and an immunostimulatory peptide FTKPRF modified with Fmoc (Fmoc-FTKPRF) as hydrogel monomers. These monomers further utilize non-covalent bond forces such as hydrogen bonds, hydrophobic interactions, and x-x stacking to co-assemble into a hydrogel within a short time at 37° C. The bionic hybrid polypeptide hydrogel is injectable and can serve as a drug reservoir implanted into cavities formed after tumor surgery. The drugs loaded in the hydrogel are slowly released at a stable and controlled rate and appropriate concentration within the post-surgical cavity, thereby effectively killing residual tumor cells while avoiding the toxic side effects of systemic drug administration.

The present invention relates to a fusion protein that specifically binds to the extradomain B of fibronectin (EDB-FN) and transforming growth factor β (TGF-β), and use thereof; and, more specifically, to a fusion protein comprising a polypeptide that specifically binds to EDB-FN and a polypeptide that specifically binds to TGF-β, and use thereof.The fusion protein according to the present invention fixes TGF-β, which plays an important role in antitumor immune responses, to the extracellular matrix, in order to localize the inhibition of TGF-β directly in the tumor microenvironment and ensure a local rather than systemic effect, thus showing an excellent anticancer effect in all carcinomas, including pancreatic cancer, in which the usual TGF-β inhibitors do not act due to the rigidity of the extracellular matrix, so that it can be used effectively for the prevention or treatment of cancer.

An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.

Disclosed are compositions, compounds, and methods relating to peptides that can target and home to cancer, tumors, and extracellular matrix. This is based on the discovery of peptides that can specifically bind to fibronectin extra domain B (FN-EDB), tenascin-C C domain (TNC-C), or both.

The present disclosure relates to antibody drug conjugates (ADCs) targeting human claudin 18 homolog 2 (CLDN18.2) and uses thereof, and more particularly to ADCs comprising an antibody or antigen-binding fragment thereof that binds to human CLDN18.2 and a topoisomerase I inhibitor (e.g., camptothecin); and uses of the ADCs for treating and / or treating diseases, more especially hyperproliferative and / or angiogenic diseases, e.g., cancer diseases.

The invention discloses a continuous protein rapid detection test strip and a preparation method thereof, the adopted technology is an immunochromatography method, and the reaction principle is a competition method. The test strip comprises a bottom plate, and a blood filter pad, a conjugate pad 1, a conjugate pad 2, a nitrocellulose membrane and a water absorption pad which are arranged on the bottom plate, the blood filtering pad is prepared after being treated by the pretreatment liquid; the conjugate pad 1 is coated with a zonulin polyclonal antibody marked by fluorescent microspheres and a chicken IgY antibody marked by fluorescence; the conjugate pad (2) is coated with a biotinylated zonulin antigen; the nitrocellulose membrane is provided with a detection line and a quality control line, and the detection line is coated with an anti-biotin antibody; and the quality control line is coated with a rabbit anti-chicken IgY antibody. According to the invention, not only can whole blood, serum and plasma samples be directly and rapidly detected, but also an excrement sample can be detected, the structure is simple, small and portable, and a simpler, more convenient and faster method is provided for rapid detection and screening of zonulin.

This invention provides a complex protein composition, product, and application for improving skin condition. The complex protein composition includes type IV collagen, type VII collagen, type XVII collagen, laminin 332, and fibronectin. This complex protein composition helps to improve skin condition, delay the appearance of aging, reduce wrinkles, and improve sagging. Simultaneously, it plays a positive role in repairing and supporting the skin barrier and extracellular matrix structure, which is beneficial for maintaining the stability and orderly remodeling of the skin microenvironment.

The invention discloses a preparation method of engineered extracellular vesicles for extracting and delivering functional membrane proteins. According to the preparation method of the engineered extracellular vesicles, cells are transferred into a cell culture dish coated with collagen or fibronectin for adherent culture through a cell line for stably expressing target membrane protein, and a continuous centrifugal purification process is combined, so that the novel engineered extracellular vesicles can be directly formed by shearing from the surface of a cell membrane; the method has the advantages of high yield, complete membrane protein conformation and the like, and a large number of extracellular vesicles loaded with functional GPCR are collected. Compared with a traditional exosome delivery system, adverse effects on GPCR conformation and orientation caused by internalization, acidification and other intracellular processes are avoided, and the structure and function of membrane protein on a natural cell membrane can be effectively reserved. The engineered extracellular vesicle disclosed by the invention can be efficiently taken by recipient cells, and directional transmission of GPCR among cells is realized, so that intercellular communication is accurately regulated and controlled, and efficient extraction and directional transmission of GPCR are realized. The invention provides a brand new strategy for efficient delivery of intercellular GPCR, and has wide application prospects in the fields of basic biological research, acellular therapy and the like.

The present invention relates to fibronectin-binding peptides according to the sequenceFnI5BS-L1-FnI4BS-L2-FnI3BS-L3-FnI2BSwhich are useful in tumor or fibrosis diagnosis and therapy. Instant peptides show improved fibronectin-binding and biodistribution properties compared to the prior art. Furthermore, instant peptides may be conjugated to a payload and are useful in the treatment and / or prevention of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis. Instant peptides are also useful in diagnosis of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis.

Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.